Publications

2018

Meador LR, Hastings KT. Gamma-interferon-inducible lysosomal thiol reductase; In textbook of Encyclopedia of Signaling Molecules; Springer; New York, NY; 2018; Sangdun Choi, ed; 2nd edition. (Full text)

2017

Rausch MP, Hastings KT; Immune checkpoint inhibitors in the treatment of melanoma: from basic science to clinical application; In textbook of Cutaneous Melanoma: Etiology and Therapy; Codon Publications, Brisbane, Australia; 2017; Ward, WH, Farma, JM, eds. PMID: 29461774 (Full text)

Hastings KT, Elizalde D, Muppana L, Levine S, Kamel CM, Ingram W, Kirkpatrick JT, Hu C, Rausch MP, Gallitano AL; Nab2 maintains thymus cellularity with aging and stress, Molecular Immunology, 2017; 85:185-195. PMID: 28282643 (Full text)

2016

Nguyen J, Bernert R, In K, Kang P, Sebastiao N, Hu C, Hastings KT; Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma, Melanoma Reseach; 2016; 26(2):125-37. PMID: 26930048 (Full text)

2015

Rausch MP, Hastings KT; Diverse cellular and organismal functions of the lysosomal thiol reductase GILT, Molecular Immunology; 2015; 68(2 Pt A):124-8. PMID: 26116226 (Full text)

Rausch MP, Hastings KT; An exhaustion-like phenotype constrains the activity of  CD4+ T cells specific for a self and melanoma antigen, PLoS One; 2015; 10(4):e0123332. PMID: 25875653 (Full text)

2014

Rausch MP, Hastings KT;  Innate and adaptive immune responses to cancer; pp 81-122; In textbook of Fundamentals of Cancer Prevention; Springer-Verlag, New York, NY; 2014; Alberts, DS, Hess, LM, eds.; 3^rd edition. (Full text)

2013

Hastings KT, GILT: shaping the MHC class II-restricted peptidome and CD4+ T cell-mediated immunity, Frontiers in Immunology; 2013; 4:429. PMID: 24409178 (Full text)

Phipps-Yonas H, Cui H, Sebastiao N, Brunhoeber PS, Haddock E, Deymier MJ, Klapper W, Lybarger L, Roe DJ, Hastings KT; Low GILT expression is associated with poor survival in diffuse large B-cell lymphoma, Frontiers in Immunology; 2013; 4:425. PMID: 24409177 (Full text)

Phipps-Yonas H, Semik V, Hastings KT; GILT expression in B cells diminishes cathepsin S steady-state protein expression and activity, European Journal of Immunology; 2013; 43(1): 65-74. PMID: 23012103 (Full text)

2012

Rausch MP, Hastings KT; GILT modulates CD4⁺ T cell tolerance to the melanocyte differentiation antigen tyrosinase-related protein 1, Journal of Investigative Dermatology; 2012; 132(1):154-162. PMID: 21833020 (Full text)

• Highlighted with a Commentary: Becker JC, Schrama D; Control of central and peripheral tolerance to melanocyte differentiation antigens by GILT, Journal of Investigative Dermatology; 2012; 132(1):15-17.

2011

Hastings KT, Cresswell P. Disulfide reduction in the endocytic pathway: immunological functions of gamma interferon–inducible lysosomal thiol reductase, Antioxidants & Redox Signaling; 2011; 15(3):657-68. PMID: 21506690 (Full text)

2010

Rausch MP, Irvine KR, Antony PA, Restifo NP, Cresswell P, Hastings KT; GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1, Journal of Immunology; 2010; 185(5):2828-35. PMID: 20668223 (Full text)

Hastings KT, Glusac EJ, Wilson LD, Girardi M; Mycosis fungoides and Sézary syndrome: pathophysiology and pathology; In textbook of Lymphoid Neoplasms; Hodder Arnold, London, England; 2010; Magrath, I, ed.; 3^rd edition. (Full text)

2008

Hastings KT; Innate and adaptive immune responses to cancer; In textbook of Fundamentals of Cancer Prevention; Springer-Verlag, New York, NY; 2008; Alberts, DS, Hess, LM, eds.; 2^nd edition. (Full text)

2006

Hastings KT, Lackman, RL, Cresswell, P; Functional requirements for the lysosomal thiol reductase GILT in MHC class II-restricted antigen processing; Journal of Immunology; 2006; 177 (12):8569-8577. PMID: 17142755 (Full text)

2005

Taraszka KS; Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis; pp 270-271; In textbook of Field Guide to Internal Medicine; Lippincott Williams and Wilkins, Philadelphia, PA; 2005; Smith, D, Sullivan, L, Hay, S, eds.

2004

Chavel S, Taraszka KS, Schaffer JV, Lazova R, Schechner JS; Calciphylaxis associated with acute, reversible renal failure in the setting of alcoholic cirrhosis; Journal of the American Academy of Dermatology; 2004; 50 (5):S125-S128. PMID: 15097947

Taraszka KS, Dover JS; Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis; pp 893-895; In textbook of Conn’s Current Therapy; Saunders, Philadelphia, PA; 2004; Rakel, RE, Bope, ET, eds.

2003

Taraszka K, Girardi M; Treatment of cutaneous T cell lymphoma: advances in understanding disease behavior and implications for management; pp 1-26; Monograph published in Year Book of Dermatology and Dermatologic Surgery; Mosby, St. Louis, MO; 2003; Theirs, BH, Lang, PG eds.

• Featured as the Special Focus Article on Clinical Dermatology for the Year Book annual review series

2000

Taraszka KS, Higgins JMG, Tan K, Mandelbrot DA, Wang JH, Brenner MB; Molecular basis of integrin α_Eβ₇ recognition of E-cadherin; Journal of Experimental Medicine; 2000; 191 (9):1555-1567. PMID: 10790430 (Full text)

• Featured on the cover of this issue (shown on right) 

1991

Taraszka KS, Chen E, Metzger T, Chance MR; Identification of structural markers in vitamin B₁₂ and other corrinoid derivatives in solution using FTIR spectroscopy; Biochemistry; 1991; 30:1222-1227. PMID: 1991101